INSIGHTEC's Focused Ultrasound Earns Positive NICE Guidance for Treatment of Essential Tremor

PR74066

LONDON, June 21, 2018 /PRNewswire=KYODO JBN/ --

    INSIGHTEC's Focused Ultrasound Earns Positive NICE Guidance for Treatment

of Essential Tremor

    Unilateral MRI-guided Focused Ultrasound Thalamotomy for

Treatment-resistant Essential Tremor Recognised by National Institute for

Health and Care Excellence

    INSIGHTEC(R), a global medical technology innovator of incisionless

surgery, announced today that The National Institute for Health and Care

Excellence (NICE) issued a positive NICE guidance for unilateral MRI-guided

focused ultrasound thalamotomy for treatment-resistant essential tremor (ET).

ET affects more than one million people in the UK and impacts their ability to

perform everyday tasks due to uncontrollable shaking of their hands.

    The Trust Imperial College Healthcare NHS Trust is the first and only site

in the UK with the Exablate Neuro(TM) technology to treat essential tremor. To

date 16 patients with ET have been treated at St. Mary's by an expert,

multidisciplinary team including Professor Wladyslaw Gedroyc, Consultant

Radiologist, Dr. Peter Bain, Consultant Neurologist and Professor Dipankar

Nandi, Consultant Neurosurgeon.

    "Essential tremor patients treated at St Mary's have experienced very

substantial improvement in the severity of their tremor as well as their

quality of life," commented Professor Dipankar Nandi, Consultant Neurosurgeon

and Head of Department, St Mary's Hospital, Imperial College Healthcare NHS

Trust. "In addition, the safety profile is favorable with minor, often

temporary side effects experienced by this group."

    During the treatment, ultrasound waves pass safely through the skull to

ablate a tiny spot in the brain considered to be responsible for the tremor.

The result is often an immediate improvement of the tremor in the treated hand.

Due to the incisionless nature of focused ultrasound, there is no risk of

infection and patients recover quickly.

    "The positive NICE guidance adds to the growing body of positive health

technology determinations for incisionless brain surgery using INSIGHTEC's

Exablate Neuro," said Maurice R. Ferre, MD , Chief Executive Officer and

Chairman of the Board of INSIGHTEC. "This is a critical step toward increased

patient access to our technology around the globe that."

    For more information on the NICE guidance, please visit NICE.org.uk.

    About INSIGHTEC

    INSIGHTEC is a global medical technology innovator transforming patient

lives through incisionless brain surgery using MR-guided focused ultrasound.

The company's award-winning Exablate Neuro(TM) is used by neurosurgeons to

perform the Neuravive(TM) treatment to deliver immediate and durable tremor

relief for essential tremor patients.  Research for future applications in the

neuroscience space is underway in partnership with leading academic and medical

institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida,

with offices in Dallas, Tokyo and Shanghai.

    For more information, please visit: http://www.insightec.com/

    Forward-looking Statements

    This press release contains forward-looking statements regarding, among

other things, statements pertaining to expectations, goals, plans, objectives,

and future events.  INSIGHTEC intends such forward-looking statements to be

covered by the safe harbor provisions for forward-looking statements contained

in Section 21E of the Securities Exchange Act of 1934, and the Private

Securities Reform Act of 1995. In some cases, forward-looking statements can be

identified by the following words: "may," "can," "will," "could," "would,"

"should," "expect," "intend," "plan," "anticipate," "believe," "estimate,"

"predict," "project," "potential," "promise," "continue," "ongoing," or the

negative of these terms or other comparable terminology, although not all

forward-looking statements contain these words. These statements are based on

the current estimates and assumptions of our management as of the date of this

press release and are subject to risks, uncertainties, changes in

circumstances, assumptions, and other factors that may cause actual results to

differ materially from those indicated by forward-looking statements, many of

which are beyond INSIGHTEC's ability to control or predict. Given these

uncertainties, undue reliance should not be placed on these forward-looking

statements. INSIGHTEC does not undertake any obligation to release publicly any

updates or revisions to these forward-looking statements to reflect events or

circumstances after the date of this press release or to reflect the occurrence

of unanticipated events.

    "Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether

standing alone or in connection with the word " INSIGHTEC" are protected

trademarks of INSIGHTEC.

    Media contacts:

Jessica Dixon

Spider for INSIGHTEC

INSIGHTEC@wearespider.com

0207-403-6900

    Source: INSIGHTEC